L
L. Michael Glode
Researcher at University of Colorado Denver
Publications - 70
Citations - 3711
L. Michael Glode is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 27, co-authored 69 publications receiving 3478 citations. Previous affiliations of L. Michael Glode include University of Colorado Boulder & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff,T. Schuetz,Brent A. Blumenstein,L. Michael Glode,David L. Bilhartz,Michael S. Wyand,Kelledy Manson,Dennis Panicali,Reiner Laus,Jeffrey Schlom,William L. Dahut,Philip M. Arlen,James L. Gulley,Wayne R. Godfrey +13 more
TL;DR: PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC, providing preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study.
Journal ArticleDOI
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
Thomas W. Flaig,Daniel L. Gustafson,Lih-Jen Su,Joseph A. Zirrolli,Frances Crighton,Gail S. Harrison,A. Scott Pierson,Rajesh Agarwal,L. Michael Glode +8 more
TL;DR: It is concluded that 13 g of oral silybin-phytosome daily, in 3 divided doses, appears to be well tolerated in patients with advanced prostate cancer and is the recommended phase II dose.
Journal ArticleDOI
Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Isabel R. Schlaepfer,Leah Rider,Lindsey Ulkus Rodrigues,Miguel A. Gijón,Colton T. Pac,Lina Romero,Adela Cimic,S. Joseph Sirintrapun,L. Michael Glode,Robert H. Eckel,Scott D. Cramer +10 more
TL;DR: Systemic treatment with etomoxir in nude mice resulted in decreased xenograft growth over 21 days, underscoring the therapeutic potential of blocking lipid catabolism to decrease prostate cancer tumor growth.
Journal ArticleDOI
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial†
Ali M. Ziada,Albaha Barqawi,L. Michael Glode,Marileila Varella-Garcia,Frances Crighton,Susan Majeski,Mark Rosenblum,Madeleine A. Kane,Lin Chen,E. David Crawford +9 more
TL;DR: To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC).
Journal ArticleDOI
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
TL;DR: The current study was designed to evaluate the efficacy and toxicity of the continuous oral administration of a combination of cyclophosphamide and dexamethasone in patients with prostate specific antigen (PSA) progression despite single or multiagent hormone therapy and antiandrogen withdrawal.